Results 31 to 40 of about 28,236 (118)

Nonglycemic effects of dipeptidyl peptidase-4 inhibitors

Терапевтический архив, 2013
The review considers the major nonglycemic effects of dipeptidyl peptidase-4 inhibitors commonly used in diabetological practice, by using as an example sitagliptin, the first and most investigated representative of this class.
A S Ametov, L L Kamynina
doaj  

Henoch–Schönlein purpura induced by sitagliptin: A case report

SAGE Open Medical Case Reports
Dipeptidyl peptidase-4 inhibitors are oral antihyperglycemic medications often used as adjuncts to other antidiabetic agents to treat type 2 diabetes mellitus.
Alexa Moschella, Carly Kirshen
doaj   +1 more source

Identification of Risk Factors for Gliptin-associated Bullous Pemphigoid among Diabetic Patients

Acta Dermato-Venereologica
Drug-associated bullous pemphigoid has been shown to follow long-term gliptin (dipeptidyl-peptidase 4 inhibitors) intake. This study aimed at identifying risk factors for gliptin-associated bullous pemphigoid among patients with type 2 diabetes.
Dana Shalmon, Efrat Bar-Ilan, Alon Peled, Shamir Geller, Jonathan Bar, Naama Schwartz, Eli Sprecher, Mor Pavlovsky   +7 more
doaj   +1 more source

Acute pancreatitis with gliptins: Is it a clinical reality?

Indian Journal of Endocrinology and Metabolism, 2013
There are reports of acute pancreatitis with the use of dipeptidyl peptidase-4 inhibitors (gliptins). This class of drugs is widely being prescribed for type 2 diabetes mellitus (DM) in our country.
Muthukrishnan Jayaraman, Sandeep Kumar, Atul Kumar Sood   +2 more
doaj   +1 more source

The clinical effectiveness of sodium-glucose co-transporter-2 inhibitors on prognosis of patients with chronic obstructive pulmonary disease and diabetes

Nature Communications
Diabetes is common in patients with chronic obstructive pulmonary disease. Sodium-glucose co-transporter-2 inhibitors are effective in treating type 2 diabetes and provide benefits for conditions like cardiovascular and kidney diseases.
Jheng-Yan Wu, Khai-Chi Hu, Mei-Yuan Liu, Yu-Jou Wu, Wan-Hsuan Hsu, Ya-Wen Tsai, Ting-Hui Liu, Po-Yu Huang, Min-Hsiang Chuang, Tsung Yu, Kuang-Ming Liao, Chih-Cheng Lai   +11 more
doaj   +1 more source

Hypoglycemic Coma in a Hemodialysis Patient Receiving Blood Glucose-Lowering Therapy With the Single Agent Teneligliptin

Clinical Medicine Insights: Case Reports, 2018
Blood glucose management in patients undergoing dialysis is clinically challenging. In this population, most conventional oral hypoglycemic agents are contraindicated, especially from the perspective of pharmacokinetics. Dipeptidyl peptidase-4 inhibitors
Takumi Minezumi, Shin-ichi Takeda, Yusuke Igarashi, Kentaro Sato, Yoshiaki Murakami, Daisuke Nagata   +5 more
doaj   +1 more source

Effects of metformin and alogliptin on body composition in people with type 2 diabetes

Journal of Diabetes Investigation, 2019
Aims/Introduction The aim of the present study was to investigate the effects of metformin and a dipeptidyl peptidase‐4 inhibitor, alogliptin, on body composition in a 12‐week randomized add‐on trial in Japanese participants with type 2 diabetes ...
Yumie Takeshita, Yuki Kita, Ken‐ichiro Kato, Takehiro Kanamori, Hirofumi Misu, Shuichi Kaneko, Toshinari Takamura   +6 more
doaj   +1 more source

Sodium-glucose cotransporter 2 inhibitors combined with dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: a review of current clinical evidence and rationale

Drug Design, Development and Therapy, 2017
Sayf A Yassin,1 Vanita R Aroda2 1MedStar Union Memorial Hospital, Baltimore, 2MedStar Health Research Institute, Hyattsville, MD, USA Abstract: Type 2 diabetes mellitus (T2DM) is a progressive and multifactorial cardiometabolic disorder. Almost half of
Yassin SA, Aroda VR
doaj  

The multiple actions of dipeptidyl peptidase 4 (DPP-4) and its pharmacological inhibition on bone metabolism: a review

Diabetology & Metabolic Syndrome
Background Dipeptidyl peptidase 4 (DPP-4) plays a crucial role in breaking down various substrates. It also has effects on the insulin signaling pathway, contributing to insulin resistance, and involvement in inflammatory processes like obesity and type ...
L. M. Pechmann, F. I. Pinheiro, V. F. C. Andrade, C. A. Moreira   +3 more
doaj   +1 more source

Minimizing the risk of hypoglycemia in patients with type 2 diabetes mellitus

Diabetes, Metabolic Syndrome and Obesity, 2010
Pamela KushnerUniversity of California, Irvine College of Medicine, California, USAAbstract: Hypoglycemia is a major barrier to achieving glycemic goals in patients with diabetes.
Kushner P
doaj   +2 more sources